About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Ivarmacitinib

Company: Huijie Zhang
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Trial details

Recruiting NCT NCT06519526

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Not yet reported Fudan University 25 participants Est. completion 2027-08-31 1 site

Other conditions: Relapsed/Refractory Peripheral T Cell Lymphoma
View official trial listing →
Recruiting NCT NCT07251595

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 176 participants Est. completion 2027-09 1 site

Other conditions: Non-segmental Vitiligo
View official trial listing →
Recruiting NCT NCT07270003

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

Not yet reported Xijing Hospital 60 participants Est. completion 2026-10-01 1 site

Other conditions: Palmoplantar Pustulosis (PPP)
View official trial listing →
Recruiting NCT NCT07570745

Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 82 participants Est. completion 2029-05-01 1 site Stand-alone

Other conditions: Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation
View official trial listing →
Status unknown NCT NCT02423538

First-in-Human Single Ascending Dose of SHR0302

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 64 participants 1 site

Other conditions: Rheumatoid Arthritis
View official trial listing →
Status unknown NCT NCT02665910

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 48 participants 1 site

Other conditions: Rheumatoid Arthritis
View official trial listing →
Status unknown NCT NCT02892370

Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 14 participants Est. completion 2016-10 1 site

Other conditions: Rheumatoid Arthritis
View official trial listing →
Completed NCT NCT03254966

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 194 participants Est. completion 2019-10-12 1 site

Other conditions: Rheumatoid Arthritis
View official trial listing →
Completed NCT NCT03675477

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

Not yet reported Reistone Biopharma Company Limited 164 participants Est. completion 2021-02-03 67 sites

Other conditions: Ulcerative Colitis
View official trial listing →
Completed NCT NCT03677648

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

Not yet reported Reistone Biopharma Company Limited 112 participants Est. completion 2021-12-09 82 sites

Other conditions: Crohn's Disease
View official trial listing →
Completed NCT NCT04146207

SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 28 participants Est. completion 2024-10-31 2 sites

Other conditions: Chronic GVHD
View official trial listing →
Completed NCT NCT04162899

A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Not yet reported Reistone Biopharma Company Limited 105 participants Est. completion 2020-08-31 23 sites

Other conditions: Atopic Dermatitis
View official trial listing →
Completed NCT NCT04293029

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2020-12-30 1 site

Other conditions: Hepatic Impairment
View official trial listing →
Completed NCT NCT04333771

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 566 participants Est. completion 2023-09-21 1 site

Other conditions: Rheumatoid Arthritis
View official trial listing →
Completed NCT NCT04346316

A Phase II Study in Patients With Alopecia Areata

Not yet reported Reistone Biopharma Company Limited 94 participants Est. completion 2021-06-29 34 sites

Other conditions: Alopecia Areata
View official trial listing →
Completed NCT NCT04481139

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

Not yet reported, Not yet reported Jiangsu HengRui Medicine Co., Ltd. 504 participants Est. completion 2023-05-12 1 site

Other conditions: Ankylosing Spondylitis
View official trial listing →
Completed NCT NCT04712838

Study on the Bioavailability of SHR0302 in Healthy Subjects

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2021-04-13 1 site

Other conditions: Healthy Subjects
View official trial listing →
Status unknown NCT NCT05181137

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Not yet reported Reistone Biopharma Company Limited 368 participants Est. completion 2025-03-31 113 sites

Other conditions: Ulcerative Colitis
View official trial listing →
Status unknown NCT NCT05324631

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 300 participants Est. completion 2024-12-11 1 site

Other conditions: Non-radiographic Axial Spondyloarthritis
View official trial listing →
Completed NCT NCT05392127

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2022-08-18 1 site

Other conditions: Rheumatoid Arthritis
View official trial listing →
Status unknown NCT NCT05470413

Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Not yet reported Reistone Biopharma Company Limited 330 participants Est. completion 2024-02-15 31 sites

Other conditions: Alopecia Areata
View official trial listing →
Completed NCT NCT05856058

To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Not yet reported Jiangsu HengRui Medicine Co., Ltd. 16 participants Est. completion 2023-10-09 1 site

Other conditions: Graft-versus-host Disease
View official trial listing →
Status unknown NCT NCT05900089

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Not yet reported Henan Cancer Hospital 30 participants Est. completion 2026-06-01 1 site

Other conditions: Peripheral T Cell Lymphoma
View official trial listing →
Not yet recruiting NCT NCT06731153

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Not yet reported Fudan University 40 participants Est. completion 2027-12 1 site Stand-alone

Other conditions: Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer
View official trial listing →
Not yet recruiting NCT NCT07266168

Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica

Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 80 participants Est. completion 2028-11-30

Other conditions: Polymyalgia Rheumatics (PMR)
View official trial listing →
Not yet recruiting NCT NCT07276620

Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults

Not yet reported Xiangya Hospital of Central South University 1000 participants Est. completion 2029-01-30 Stand-alone

Other conditions: Atopic Dermatitis (AD)
View official trial listing →
Not yet recruiting NCT NCT07313202

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Not yet reported Fujian Cancer Hospital 72 participants Est. completion 2028-12-26 Stand-alone

Other conditions: Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
View official trial listing →
Not yet recruiting NCT NCT07324473

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

Not yet reported First Affiliated Hospital of Chongqing Medical University 65 participants Est. completion 2029-01-01 1 site Stand-alone

Other conditions: Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
View official trial listing →
Not yet recruiting NCT NCT07381114

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 32 participants Est. completion 2027-12-30 Stand-alone

Other conditions: aGVHD
View official trial listing →
Not yet recruiting NCT NCT07451665

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Not yet reported Chinese SLE Treatment And Research Group 180 participants Est. completion 2029-03-31 20 sites Stand-alone

Other conditions: Takayasu Arteritis (TAK)
View official trial listing →
Not yet recruiting NCT NCT07452445

Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis

Not yet reported Tongji Hospital 100 participants Est. completion 2029-03-01 Stand-alone

Other conditions: Rheumatoid Arthritis
View official trial listing →
Not yet recruiting NCT NCT07505186

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 45 participants Est. completion 2033-12-31 1 site Stand-alone

Other conditions: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
View official trial listing →
Not yet recruiting NCT NCT07550452

Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study

Not yet reported Peking University People's Hospital 300 participants Est. completion 2027-07-31 Stand-alone

Other conditions: Atopic Dermatitis (AD)
View official trial listing →
Withdrawn NCT NCT07634848

Ivarmacitinib for Refractory Behcet's Syndrome

Not yet reported Liu Tian Est. completion 2027-05-31 1 site Stand-alone

Other conditions: Behcet's Syndrome
View official trial listing →
Not yet recruiting NCT NCT07641010

PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma

Not yet reported, Not yet reported Shanghai Jiao Tong University School of Medicine 112 participants Est. completion 2030-09-30 1 site

Other conditions: Hodgkin Lymphoma
View official trial listing →
Not yet recruiting NCT NCT07814664

Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus

Not yet reported, Not yet reported Chinese SLE Treatment And Research Group 294 participants Est. completion 2028-09-30 1 site Stand-alone

Other conditions: Systemic Lupus Erthematosus
View official trial listing →
Not yet recruiting NCT NCT07845955

JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D

Not yet reported Huijie Zhang 132 participants Est. completion 2029-12-31 1 site Stand-alone

Other conditions: T1DM - Type 1 Diabetes Mellitus
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07845955

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.